See more : Primega Group Holdings Limited (PGHL) Income Statement Analysis – Financial Results
Complete financial analysis of Marker Therapeutics, Inc. (MRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Marker Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vy Global Growth (VYGG-WT) Income Statement Analysis – Financial Results
- The Walt Disney Company (WDP.F) Income Statement Analysis – Financial Results
- Parade Technologies, Ltd. (4966.TWO) Income Statement Analysis – Financial Results
- Banestes S.A – Banco do Estado do Espírito Santo (BEES4.SA) Income Statement Analysis – Financial Results
- Broadex Technologies Co., Ltd. (300548.SZ) Income Statement Analysis – Financial Results
Marker Therapeutics, Inc. (MRKR)
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.31M | 9.00M | 1.24M | 466.79K | 213.19K | 205.99K | 183.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.05K | 120.72K |
| Cost of Revenue | 10.42M | 3.68M | 3.16M | 18.88M | 12.76M | 124.00M | 5.25M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.63K | 38.60K |
| Gross Profit | -7.11M | 5.32M | -1.92M | -18.41M | -12.55M | -123.79M | -5.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.42K | 82.12K |
| Gross Profit Ratio | -214.60% | 59.13% | -154.70% | -3,944.85% | -5,887.41% | -60,094.84% | -2,768.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 89.50% | 68.03% |
| Research & Development | 10.42M | 26.14M | 27.79M | 18.88M | 12.76M | 124.00M | 5.25M | 3.80M | 1.71M | 189.00K | 661.63K | 1.06M | 203.73K | 290.05K | 93.04K | 182.34K | 425.57K | 173.17K | 248.36K | 1.04M | 1.73M | 833.59K | 0.00 | 341.19K | 294.92K |
| General & Administrative | 7.48M | 12.82M | 12.92M | 10.47M | 9.98M | 24.38M | 6.41M | 4.69M | 4.45M | 3.18M | 2.00M | 4.42M | 2.43M | 3.65M | 4.10M | 1.31M | 2.08M | 708.71K | 593.67K | 1.61M | 4.01M | 1.41M | 379.86K | 1.13M | 834.02K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.48M | 12.82M | 12.92M | 10.47M | 9.98M | 24.38M | 6.41M | 4.69M | 4.45M | 3.18M | 2.00M | 4.42M | 2.43M | 3.65M | 4.10M | 1.31M | 2.08M | 708.71K | 593.67K | 1.61M | 4.01M | 1.41M | 379.86K | 1.13M | 834.02K |
| Other Expenses | 0.00 | -232.97K | -2.41M | 0.00 | 0.00 | 116.05M | -183.06K | 1.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.74K | 7.48K | 5.97K | 6.37K | 147.53K | 37.45K | 42.37K | 40.77K | 0.00 | 20.64K | 17.71K |
| Operating Expenses | 17.89M | 38.96M | 40.72M | 29.35M | 22.74M | 148.38M | 11.48M | 8.26M | 6.16M | 3.37M | 2.66M | 5.48M | 2.64M | 3.94M | 4.19M | 1.50M | 2.51M | 888.25K | 989.56K | 2.68M | 5.78M | 2.28M | 379.86K | 1.49M | 1.15M |
| Cost & Expenses | 17.89M | 38.96M | 40.72M | 29.35M | 22.74M | 148.38M | 11.48M | 8.26M | 6.16M | 3.37M | 2.66M | 5.48M | 2.64M | 3.94M | 4.19M | 1.50M | 2.51M | 888.25K | 989.56K | 2.68M | 5.78M | 2.28M | 379.86K | 1.49M | 1.19M |
| Interest Income | 539.16K | 248.06K | 5.70K | 148.74K | 1.08M | 253.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.81K | 0.00 | 0.00 | 0.00 | 3.96K | 0.00 | 0.00 | 125.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.93K | 575.54K | 1.76M | 745.07K | 679.33K | 1.24M | 1.19M | 778.18K | 1.38M | 446.60K | 116.82K | 0.00 | -5.78M | -2.28M | -379.86K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.79M | 3.68M | 3.16M | 1.08M | 286.58K | 148.17M | 11.48M | 8.49M | -27.90M | -26.94M | -466.28K | 1.11M | 1.29M | 93.84K | 3.74K | 7.48K | 5.97K | 6.37K | 71.51K | 37.45K | 42.37K | 40.89K | -4.68K | 20.64K | 17.71K |
| EBITDA | -11.79M | -19.79M | -36.32M | -27.63M | -22.03M | -147.97M | -11.30M | 6.04M | -34.06M | -30.31M | -3.78M | -5.58M | 0.00 | -3.85M | -3.27M | -1.41M | -2.51M | -851.42K | -838.07K | -2.65M | -5.74M | -2.24M | -379.86K | -457.20K | -1.05M |
| EBITDA Ratio | -356.14% | -291.69% | -2,924.62% | -5,964.44% | -10,441.30% | -71,910.65% | -6,543.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,476.07% | -815.17% |
| Operating Income | -14.58M | -29.95M | -39.48M | -28.89M | -22.53M | -148.17M | -11.66M | -8.49M | -6.16M | -3.37M | -3.31M | -6.22M | -2.64M | -3.94M | -5.38M | -2.28M | -2.51M | -888.25K | -989.56K | -2.68M | -5.78M | -2.28M | -379.86K | -1.47M | -1.06M |
| Operating Income Ratio | -440.37% | -332.56% | -3,179.32% | -6,188.25% | -10,567.28% | -71,930.07% | -6,371.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,857.63% | -881.85% |
| Total Other Income/Expenses | 539.16K | 15.09K | -2.40M | 179.74K | 1.10M | 213.72K | 497.87K | 6.04M | -27.91M | -27.51M | -2.87M | -373.57K | 607.92K | -1.15M | -268.53K | -695.52K | -1.38M | -416.14K | 29.69K | 0.00 | 0.00 | 0.00 | -4.68K | 460.51K | -62.80K |
| Income Before Tax | -14.04M | -29.93M | -41.88M | -28.71M | -21.43M | -147.96M | -10.98M | -2.46M | -34.07M | -30.88M | -5.53M | -5.86M | -2.03M | -5.09M | -4.46M | -2.20M | -3.89M | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Income Before Tax Ratio | -424.09% | -332.40% | -3,372.68% | -6,149.74% | -10,050.92% | -71,826.32% | -5,999.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,156.80% | -933.87% |
| Income Tax Expense | 3.68K | -15.09K | -5.70K | -179.74K | -1.10M | -213.72K | -680.93K | -6.04M | 27.90M | 26.94M | 466.28K | -1.11M | -1.29M | -93.84K | 4.46M | 2.20M | 3.89M | 1.30M | 989.56K | 2.68M | 5.78M | 2.28M | 384.54K | 1.29M | 1.13M |
| Net Income | -14.05M | -29.92M | -41.87M | -28.53M | -20.33M | -147.96M | -10.98M | -2.46M | -34.07M | -30.88M | -5.53M | -5.86M | -2.03M | -5.09M | -4.46M | -2.20M | -3.89M | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Net Income Ratio | -424.20% | -332.23% | -3,372.22% | -6,111.23% | -9,534.57% | -71,826.32% | -5,999.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,156.80% | -933.87% |
| EPS | -1.93 | -3.58 | -5.47 | -6.06 | -4.46 | -77.50 | -11.62 | -3.56 | -93.02 | -239.63 | -584.40 | -1.07K | -529.47 | -1.54K | -1.40K | -1.12K | -2.24K | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| EPS Diluted | -1.93 | -3.58 | -5.47 | -6.06 | -4.46 | -77.50 | -11.62 | -3.31 | -93.02 | -239.63 | -584.40 | -1.07K | -529.47 | -1.54K | -1.40K | -1.12K | -2.24K | -1.30M | -989.56K | -2.68M | -5.78M | -2.28M | -384.54K | -1.29M | -1.13M |
| Weighted Avg Shares Out | 8.81M | 8.35M | 7.65M | 4.70M | 4.56M | 1.91M | 945.35K | 688.99K | 366.23K | 128.88K | 9.47K | 5.46K | 3.83K | 3.32K | 3.20K | 1.95K | 1.73K | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 8.81M | 8.35M | 7.65M | 4.70M | 4.56M | 1.91M | 945.35K | 742.10K | 366.23K | 128.88K | 9.47K | 5.46K | 3.83K | 3.32K | 3.20K | 1.95K | 1.73K | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
HOUSTON, March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the pricing of an...
Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
HOUSTON, March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has commenced an...
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results
HOUSTON, March 9, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results...
Hey Redditors, Redirect Your Attention To Marker
Hey Redditors, Redirect Your Attention To Marker
Why Cyclo, Vivos Therapeutics And More Are Moving Today
Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann-Pick Disease Type C. Cyclo Therapeutics is a U.S.-based biotechnology firm engaged in the marketing and...
Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q3 2020 Results - Earnings Call Transcript
Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q3 2020 Results - Earnings Call Transcript
Teachers 'have totally lost trust' in government's Covid competence
Approach to schools a fiasco, surveys show
UK coronavirus live: Matt Hancock says MPs will get votes on significant lockdown measures if possible
News updates: Commons debate whether to renew Coronavirus Act; PM rejects Starmer remark about widespread confusion
Teaching union warns Government schools could be forced to close again
Schools could be forced to close unless the Government takes emergency measures, a teaching union warned yesterday.
UK at 'critical point' over Covid-19, top scientists to tell public
Patrick Vallance and Chris Whitty to make televised appeal ahead of ‘challenging winter’
Source: https://incomestatements.info
Category: Stock Reports